Tilray Brands, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 19, 2019, by Tilray, Inc. (now Tilray Brands, Inc.). The filing discloses the entry into a Material Definitive Agreement to acquire FHF Holdings Ltd. ("FHF") through a wholly owned subsidiary via a plan of arrangement under British Columbia law.
Key Financial Metrics and Transaction Structure
The total consideration for the acquisition of FHF is up to C$419 million, structured as follows:
- Closing Date Consideration: C$150 million in cash and C$127.5 million in Tilray Class 2 Common Stock.
- Deferred Consideration: C$50 million in cash and C$42.5 million in Common Stock, payable six months post-closing.
- Milestone Consideration: Up to C$49 million in Common Stock, contingent on FHF achieving specific U.S. branded gross sales targets for edible or topical hemp/CBD products by December 31, 2019.
- Cash Adjustments: The cash portion of the Closing Date Consideration will be reduced by FHF's net indebtedness at closing and a transaction expense of $5,000,000.
- Stock Valuation: The "Issue Price" for stock consideration is the greater of the 15-day volume-weighted average price on Nasdaq or the lowest price permitted by Nasdaq, converted to Canadian dollars.
Note: This filing does not provide Tilray's standalone revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes and Conditions
The transaction represents a material expansion of Tilray's portfolio into the hemp and CBD sector. Key conditions and changes include:
- Approval Status: The arrangement has been approved by FHF shareholders via unanimous consent but remains subject to approval by the British Columbia Supreme Court and customary conditions precedent.
- Equity Treatment: All performance-based stock options of FHF will be cancelled. In-the-money options will fully vest and be exchanged for FHF common shares, which will then be converted into Tilray consideration. Remaining options will be cancelled.
- Timeline: The closing must occur on or before April 30, 2019, provided Nasdaq completes its review.
- Contingency: If Tilray is restricted from issuing stock or if the Issue Price falls below $56.37, stock consideration may be converted to cash.
Guidance, Risks, and Unusual Items
The filing does not contain updated financial guidance or management commentary regarding future earnings projections. The primary risk identified is the failure to meet the U.S. branded gross sales milestones required to trigger the full C$49 million Milestone Consideration. Additionally, the transaction is subject to regulatory approvals and Nasdaq review.
Investor Verification Checklist
- Verify the final net indebtedness of FHF at closing to determine the actual cash outlay.
- Monitor the British Columbia Supreme Court approval status and the April 30, 2019 closing deadline.
- Track FHF's U.S. branded gross sales of edible/topical hemp products to assess the likelihood of the C$49 million milestone payout.
- Confirm the final Issue Price of Tilray Common Stock to calculate the exact equity dilution.
- Review the Nasdaq review status regarding the issuance of unregistered securities under Section 3(a)(10).